Look back at pharma news in week to August 17

By Barbara Obstoj-Cardwell

Despite it being largely summer holiday time in the northern hemisphere, last week still provided significant interesting news in the pharma sector, not to mention trade wars in several regions with the USA’s Trump Administration. Among interesting pharma news, Motif Bio has its skin infections drug candidate iclaprim accepted for priority review by the US Food and Drug Administration. On the research front, Gemphire saw its stock decimated as it terminated a study of its liver disease drug gemcabene; and GlaxoSmithKline’s ViiV Healthcare HIV unit presented positive new data on a combination once-monthly combination drug. Meantime, Germany’s BioNTech signed a potentially lucrative deal with Pfizer for its mRNA-based flu vaccine program.

Motif Bio gets priority day with the FDA